Todd Aguilera: We must educate and rethink

Todd Aguilera, Radiation Oncologist at UT Southwestern Medical Center, recently tweeted:

“We must educate and rethink, 18 years since the last FDA approval of a drug in combo with RT. Pembro+CRT in Cervical CA! Today at the National Cancer Institute Dr. Kiran from Johnson and Johnson spent several slides talking about our own Dr. Nina Niu Sanford’s recent Journal of Clinical Oncology paper regarding disparities in RT trial expectations.

Hopefully, last week’s approval is one of several to come! Why this disparity? Is it bias or $$$ to study and earn once an approval? Let’s work with industry and cooperative groups to keep study of RT and RT combo same as another new cancer treatment. Especially as RT improves aspects of life in metastatic disease.”

Source: Todd Aguilera/X